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P U B L I S H E D B Y E L S E V I E R I N C .LettersCharacteristics and
Prognosis of Ischemic
Stroke in Young Cannabis
Users Compared With
Non-Cannabis UsersStroke is considered as a leading cause of disability
worldwide. Less than 15% of all ischemic stroke (IS)
occurs in young adults, but the consequences in this
age group are of great concern because of the longer
expected survival relative to older patients (1). The
recent increased incidence of stroke in the young has
partly been related to life-style risk factors (2), and aComparison of Clinical Characteristics and Outcome of
hemic Stroke Patients Between CU and NCU
All
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Users
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f stroke
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patent foramen ovale 22 (6.6) 2 (3.4) 20 (7.2) 0.39
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nial arterial stenosis 66 (19.8) 26 (44.8) 40 (14.5) <0.00001
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ssel disease 3 (0.9) 1 (1.7) 2 (0.7) 0.44
nial aneurism 2 (0.6) 0 2 (0.7) 1.00
mined 87 (26) 13 (22.4) 74 (26.8) 0.49
mptoms on admission
eﬁcit 200 (59.9) 30 (51.7) 170 (61.6) 0.36
101 (30.2) 11 (19) 90 (32.6) 0.040
isorders 80 (23.9) 20 (34.5) 60 (21.7) 0.039
(3-month mRS) 0 (0–1) 0 (0–1) 0 (0–1) 0.38
162 (57.2) 33 (63.5) 129 (55.8)
65 (23) 11 (21.1) 54 (23.4)
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n (%) except for the outcome 3-month mRS, which is expressed by the median
-3rd quartile). The 3-month modiﬁed Rankin scale (mRS) included 283 patients
ta were not available in patients recently enrolled in the study or lost during the
ankin scores are as follows: 0: no symptom, 1 to 5: incremental disability, 6: death.
nabis users; NCU ¼ non-cannabis users.temporal relationship between cannabis exposure
(the most frequently used illicit drug worldwide) and
the occurrence of cardiovascular events has been
recently reported (3). However, clinical and prog-
nostic characteristics of IS patients who are current
cannabis users (CU) and non-cannabis users (NCU)
were not analyzed previously.
In the present study, CU and NCU were compared
in a prospective series of IS in young adults. The
study was conducted over a 9-year period (2005
to 2014) and included all consecutive patients,
age <45 years, hospitalized for an acute IS. The use of
illicit drug (cannabis, cocaine, and amphetamines)
and the protocol of investigations were speciﬁcally
assessed as described previously (4). Neurological
symptoms were reported on admission, and the
prognosis was evaluated 3 months after the stroke by
the modiﬁed Rankin Scale.
All data were compared between CU versus NCU.
Continuous data were expressed as mean  SD and
categorical data as the number and the frequency (%).
Continuous variables were compared with the Stu-
dent t test, and categorical data were compared with
the chi-square test or with the Fisher exact test. For
the Rankin scale, data are expressed as the median/
interquartile range, and the Mann-Whitney U test was
used because values are not normally distributed.
A p value <0.05 was considered as signiﬁcant.
Of the 334 patients included in the series, 17.4%
were CU (n ¼ 58, 2 of them were also cocaine abusers).
Characteristics of both CU and NCU are detailed in
Table 1. CU were signiﬁcantly younger, more
frequently men, and consumed tobacco and alcohol
more frequently than NCU. In CU, the main etiology
of the stroke was intracranial arterial stenosis in 45%
of cases. At admission, CU displayed a 1-sided motor
deﬁcit similarly to NCU; however, CU more frequently
displayed visual disorders and less aphasia compared
with NCU. Functional independence was similar in
both subgroups. Despite a favorable prognosis in both
groups, 5 patients died after the stroke.
In addition to representing the most important
series of IS patients in CU (58 patients), the current
report provides a ﬁrst-time analysis of the charac-
teristic’s differences between CU and NCU stroke
patients. CU patients were younger, more frequently
male, and were more frequently exposed to other
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2053life-style risk factors relating to the fact that cannabis
consumption is frequently associated with tobacco
use and to some festive habits in young males (3). The
higher prevalence of intracranial arterial stenosis as a
cause of IS in CU in our series is in accordance with
the potential involved mechanisms of stroke in CU
represented by reversible cerebral vasoconstriction,
and impairment of cerebral mitochondrial respiration
induced by tetrahydrocannabinol (4,5). The revers-
ibility of vasoconstriction was also described in
peripheral arteritis associated with cannabis use (3).
Our data demonstrate that a favorable functional ca-
pacity is common in young patients suffering from
stroke independently of cannabis use that is likely
due to age-related enhanced brain plasticity. How-
ever, in the whole series, 18% of patients retained
signiﬁcant disability, along with 5 deaths.
Fighting stroke must remain a priority, including in
young adults. The ﬁrst step may be to inform the
public regarding the potential occurrence of stroke
associated with cannabis use and other life-style risk
factors (3), particularly nowadays when cannabis use
is encouraged by new legislations worldwide.
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APOC3 Loss-of-Function
Mutations With
Plasma Lipids and
Subclinical AtherosclerosisThe Multi-Ethnic BioImage StudyIn 2008, Pollin et al. (1) identiﬁed 1 mechanism of
lowering triglyceride-rich lipoproteins among the
Lancaster Amish, loss of apolipoprotein C-III (APOC3)
gene function, which was associated with reduced
subclinical atherosclerosis (i.e., coronary arterial cal-
ciﬁcation on cardiac computed tomography). We
recently extended these observations to show that
APOC3 loss-of-function mutations also reduce risk
for clinical atherosclerotic cardiovascular disease
(ASCVD) (2,3). Here, we address 2 questions related to
mutations that reduce APOC3 function: 1) do these
mutations also associate with lower plasma low-
density lipoprotein cholesterol (LDL-C); and 2) do
these mutations reduce subclinical atherosclerosis in
the general population, particularly in individuals
with ancestry outside of Europe?
We studied 6,699 individuals of European, African,
Asian, and Hispanic ancestries from the BioImage
Study (BioImage Study: A Clinical Study of Burden of
Atherosclerotic Disease in an At-Risk Population,
NCT00738725), a prospective, observational study
aimed at characterizing subclinical atherosclerosis in
U.S. adults (55 to 80 years old) at risk for clinical
ASCVD (4). We genotyped 4 APOC3 (NM_000040.1)
loss-of-function mutations (IVS2þ1G/A, A43T, R19X,
IVS3þ1G/T) using the Illumina HumanExome Bead-
Chip Array v1.1 (Illumina, San Diego, California).
Written informed consent was obtained from all
study participants according to a protocol approved
by the Western Institutional Review Board, Olympia,
Washington. Fasting blood lipids were measured
at the baseline examination. Blood lipids were
adjusted for the presence of statin medications
to reﬂect the observation that statins, on average,
reduce total cholesterol by 20% and LDL-C by 30% (5).
Noninvasive assessments for subclinical athero-
sclerosis (coronary arterial calciﬁcation [CAC],
carotid plaque, and carotid intima media thick-
ness [CIMT]) were performed at the baseline
examination on a mobile imaging facility as previ-
ously described (4).
A total of 6,395 subjects passed all quality-control
measures. Variant calling was performed using
